Table 1. Major demographic, clinical and pathological characteristics of 230 IDC patients.
| Characteristics | Value (%) | Recurrence, n (%) | Median 8-DFS (month) | 8-DFS Rate (%) | Pvalue |
|---|---|---|---|---|---|
| Age (M ± SD, yr) | 53.5 ± 11.6 | N/A | N/A | N/A | N/A |
| Tumor size (cm) | 0.777 | ||||
| 1 (≤2.0) | 64 (27.8) | 43 (67.2) | 53.0 | 32.8 | |
| 2 (2.0 - 5.0) | 133 (57.8) | 86 (64.7) | 50.1 | 35.3 | |
| 3 (≥5.0) | 33 (14.4) | 23 (69.7) | 42.9 | 30.3 | |
| Lymph node status§ | 0.011 | ||||
| 0 (0) | 77 (33.5) | 45 (58.4) | 82.0 | 41.6 | |
| 1 (1 - 3) | 66 (28.7) | 44 (66.7) | 53.0 | 33.3 | |
| 2 (4 - 9) | 56 (24.3) | 38 (67.9) | 50.1 | 32.1 | |
| 3 (≥10) | 31 (13.5) | 25 (80.6) | 25.8 | 19.4 | |
| Histologic grade# | 0.054 | ||||
| 1 | 20 (8.7) | 14 (70.0) | 76.8 | 30.0 | |
| 2 | 174 (75.6) | 109 (62.6) | 55.9 | 37.4 | |
| 3 | 36 (15.7) | 29 (80.6) | 36.6 | 19.4 | |
| ER | 0.082 | ||||
| 0 (negative) | 125 (54.3) | 86 (68.8) | 42.9 | 31.2 | |
| 1 (positive) | 105 (45.7) | 66 (62.9) | 62.0 | 37.1 | |
| HER2 | <0.001 | ||||
| 0 (negative) | 147(63.9) | 86 (58.5) | 77.7 | 41.5 | |
| 1 (positive) | 83 (36.1) | 66 (79.5) | 32.9 | 20.5 | |
| TNM stage | 0.001 | ||||
| 1 (I) | 27 (11.7) | 15 (55.6) | 92.9 | 44.4 | |
| 2 (II) | 113 (49.2) | 68 (60.2) | 52.1 | 39.8 | |
| 3 (III) | 90 (39.1) | 69 (76.7) | 32.9 | 23.3 | |
| NPI* | 0.007 | ||||
| 1 (≤2.8) | 73 (31.7) | 40 (54.8) | 87.3 | 45.2 | |
| 2 (2.8 - 4.4) | 108 (47.0) | 75 (69.4) | 49.9 | 30.6 | |
| 3 (>4.4) | 49 (21.3) | 37 (75.5) | 33.1 | 24.5 | |
N/A: not applicable; DFS: disease free survival; M: mean; SD: standard deviation; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; TNM: tumor-node-metastasis.
§The number of positive axillary lymph nodes;
#Histologic grade: Nottingham grading system, NGS12;
*NPI = tumor maximum invasive cancer size in centimeters × 0.2 + lymph node (LN) stage (1, 2, or 3) + histologic grade (1, 2, or 3)7.